Your session is about to expire
← Back to Search
AL8326 for Small Cell Lung Cancer
Study Summary
This trial is testing a new drug to treat small cell lung cancer that has come back or spread. The goal is to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had major surgery in the last 28 days or minor surgery in the last 7 days.I do not have conditions that increase my risk of bleeding significantly.I have a serious wound, ulcer, or bone fracture that isn't healing.I haven't taken strong drugs affecting liver enzymes CYP3A4, CYP2C9, and CYP2C19 in the last 14 days.I do not have serious heart or blood vessel problems.I have not coughed up blood in the last 3 months.You are expected to live for at least 3 more months.My cancer is confirmed as small cell lung cancer through testing.I am 18 years old or older.I am fully active or restricted in physically strenuous activity but can do light work.You have at least one growth in your body that can be measured according to specific guidelines.
- Group 1: OBD finding cohort at low dose
- Group 2: OBD finding cohort at middle dose
- Group 3: OBD finding cohort at high dose
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are accepted into this experiment?
"Affirmative. Evidence from clinicaltrials.gov shows that the medical study, which was launched on November 1st 2022, is currently enrolling participants. 36 people are sought for recruitment across 2 sites."
Is this clinical research actively looking for participants?
"Affirmative. Clinicaltrials.gov indicates that the trial, initially posted on November 1st 2022, is currently recruiting patients and plans to enroll 36 subjects across two sites."
Has AL8326 received governmental authorization for use in high doses?
"Due to the absence of evidence for AL8326's efficacy, our team assigned it a safety rating of 2 on a scale from 1-3. This is because this is currently still in Phase 2, presenting only some data supporting its safety."
Share this study with friends
Copy Link
Messenger